Modality
Nanobody
MOA
HPK1i
Target
JAK1
Pathway
Angiogenesis
LGSObesityBCC
Development Pipeline
Preclinical
Jul 2020
→ Mar 2030
PreclinicalCurrent
NCT05579887
165 pts·BCC
2020-07→2030-03·Terminated
165 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-284mo agoNDA· LGS
2030-03-164.0y awayInterim· BCC
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Termina…
Catalysts
NDA
2025-11-28 · 4mo ago
LGS
Interim
2030-03-16 · 4.0y away
BCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05579887 | Preclinical | BCC | Terminated | 165 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 |